TG Therapeutics
TGTX
174 hedge funds and large institutions have $454M invested in TG Therapeutics in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 68 increasing their positions, 53 reducing their positions, and 30 closing their positions.
145% more call options, than puts
Call options by funds: $27.8M | Put options by funds: $11.3M
28% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 53
2.95% more ownership
Funds ownership: 70.72% → 73.67% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 181 → 174 (-7)
10% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 30
53% less capital invested
Capital invested by funds: $965M → $454M (-$511M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28.8M |
| 2 |
Millennium Management
New York
|
+$17.4M |
| 3 |
DM
Deerfield Management
New York
|
+$16.7M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$12.3M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.6M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$14.4M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$11.1M |
| 4 |
AG
Artal Group
Luxembourg
|
-$7.61M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$5.88M |
TGTX Hedge Fund Activity: Q2 2022 in Review
174 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2022, worth a combined $454M — down 53% from $965M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of TGTX and 27 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 68 added.
The largest buyer was State Street, adding an estimated $28.8M. The largest seller was Fidelity Investments, cutting an estimated $76.6M.
- 174 institutional investors held TG Therapeutics (TGTX) as of Q2 2022, down from 181 in Q1 2022.
- Funds reported $454M of TG Therapeutics stock for Q2 2022, down 53% quarter-over-quarter.
- 27 funds opened new TG Therapeutics positions in Q2 2022 and 30 closed out, a net change of -3 holders.
- The largest TG Therapeutics buyer in Q2 2022 was State Street, an estimated $28.8M added.
- The largest TG Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $76.6M sold.
Based on aggregated 13F filings for Q2 2022.